SI2301955T1 - Cepivo proti virusu varicella zoster - Google Patents
Cepivo proti virusu varicella zoster Download PDFInfo
- Publication number
- SI2301955T1 SI2301955T1 SI200632264T SI200632264T SI2301955T1 SI 2301955 T1 SI2301955 T1 SI 2301955T1 SI 200632264 T SI200632264 T SI 200632264T SI 200632264 T SI200632264 T SI 200632264T SI 2301955 T1 SI2301955 T1 SI 2301955T1
- Authority
- SI
- Slovenia
- Prior art keywords
- individuals
- use according
- population
- adjuvant
- mpl
- Prior art date
Links
- 229940124863 Varicella-zoster virus vaccine Drugs 0.000 title 1
- 239000002671 adjuvant Substances 0.000 claims abstract 6
- 239000000203 mixture Substances 0.000 claims abstract 5
- 206010036376 Postherpetic Neuralgia Diseases 0.000 claims abstract 4
- 101900123149 Varicella-zoster virus Envelope glycoprotein E Proteins 0.000 claims abstract 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims abstract 4
- 230000002163 immunogen Effects 0.000 claims abstract 3
- 239000000427 antigen Substances 0.000 claims abstract 2
- 102000036639 antigens Human genes 0.000 claims abstract 2
- 108091007433 antigens Proteins 0.000 claims abstract 2
- 235000012000 cholesterol Nutrition 0.000 claims abstract 2
- 239000003814 drug Substances 0.000 claims abstract 2
- 206010061598 Immunodeficiency Diseases 0.000 claims 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 2
- 108020001507 fusion proteins Proteins 0.000 claims 2
- 102000037865 fusion proteins Human genes 0.000 claims 2
- 239000002502 liposome Substances 0.000 claims 2
- 208000010201 Exanthema Diseases 0.000 claims 1
- 241000701085 Human alphaherpesvirus 3 Species 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 201000005884 exanthem Diseases 0.000 claims 1
- 206010037844 rash Diseases 0.000 claims 1
- 229960005486 vaccine Drugs 0.000 claims 1
- 229940021648 varicella vaccine Drugs 0.000 claims 1
- 229940124742 varicella zoster vaccine Drugs 0.000 claims 1
- 239000012634 fragment Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
- A61K39/25—Varicella-zoster virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
- C12N2710/16722—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
- C12N2710/16734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Biotechnology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Rheumatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Claims (13)
1. Uporaba imunogenega sestavka, ki obsega VZV gE, kjer je gE skrajšan na C-koncu, da se odstrani karboksi terminalna sidrna regija, in kjer gE ni v obliki fuzijskega proteina, in TH-1 adjuvans, ki obsega QS21 in 3D-MPL, v pripravi zdravila za preprečevanje ali izboljšanje pasastega izpuščaja in/ali postherpetične nevralgije pri populaciji posameznikov, starejših od 50, in imunokompromitiranih posameznikov.
2. Uporaba po zahtevku 1, kjer so populacija posamezniki, starejši od 60.
3. Uporaba po katerem koli od predhodnih zahtevkov, kjer so populacija posamezniki, starejši od 70.
4. Uporaba po zahtevku 1, kje so populacija imunokompromitirani posamezniki.
5. Uporaba po katerem koli predhodnem zahtevku, kjer so posamezniki imeli norice ali so imeli živo varicella cepivo.
6. Uporaba po katerem koli predhodnem zahtevku, kjer se pri posameznikih virus varicella zoster ni reaktiviral.
7. Uporaba po katerem koli predhodnem zahtevku, kjer adjuvans obsega liposome, ki obsegajo holesterol.
8. Uporaba po katerem koli predhodnem zahtevku, kjer je 3D-MPL obsegan v liposomu.
9. Uporaba po katerem koli predhodnem zahtevku, kjer ima gE aminokislinsko zaporedje s SEQ ID NO:1.
10. Uporaba po katerem koli predhodnem zahtevku, kjer sestavek obsega 25 pg do 100 pggE.
11. Uporaba po katerem koli predhodnem zahtevku v 2-odmemem dostavnem režimu.
12. Komplet, ki obsega ločeni komponenti, TH-1 adjuvans in NZN gE antigen, kot sta definirana za kateri koli predhodni zahtevek, primeren za ekstemporalno pripravo vakcinskega sestavka, za uporabo v preprečevanju ali izboljšanju pasastega izpuščanja in/ali postherpetične nevralgije pri populaciji posameznikov, starejših od 50, ali imunokompromitiranih posameznikov.
13. N7N gE, ki je skrajšan na C-koncu, da se odstrani karboksi terminalna sidrna regija, in ki ni v obliki fuzijskega proteina, za uporabo v preprečevanju ali izboljšanju pasastega izpuščanja in/ali postherpetične nevralgije pri populaciji posameznikov, starejših od 50, ali imunokompromitiranih posameznikov, kjer se VZV gE daje v kombinaciji s TH-1 adjuvansom, ki obsega QS21 in 3D-MPL.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0504436.7A GB0504436D0 (en) | 2005-03-03 | 2005-03-03 | Vaccine |
| EP10188215.7A EP2301955B1 (en) | 2005-03-03 | 2006-03-01 | Varicella Zoster virus vaccine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SI2301955T1 true SI2301955T1 (sl) | 2018-07-31 |
Family
ID=34430592
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI200632265T SI2281831T1 (sl) | 2005-03-03 | 2006-03-01 | Cepivo proti virusu varicella zoster |
| SI200632264T SI2301955T1 (sl) | 2005-03-03 | 2006-03-01 | Cepivo proti virusu varicella zoster |
| SI200631890T SI1858917T1 (sl) | 2005-03-03 | 2006-03-01 | Cepivo proti virusu varicella zoster |
| SI200632138A SI2281830T1 (sl) | 2005-03-03 | 2006-03-01 | Cepivo proti virusu varicella zoster |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI200632265T SI2281831T1 (sl) | 2005-03-03 | 2006-03-01 | Cepivo proti virusu varicella zoster |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI200631890T SI1858917T1 (sl) | 2005-03-03 | 2006-03-01 | Cepivo proti virusu varicella zoster |
| SI200632138A SI2281830T1 (sl) | 2005-03-03 | 2006-03-01 | Cepivo proti virusu varicella zoster |
Country Status (35)
| Country | Link |
|---|---|
| US (3) | US20080171079A1 (sl) |
| EP (4) | EP2281830B1 (sl) |
| JP (2) | JP5420842B2 (sl) |
| KR (2) | KR20140006115A (sl) |
| CN (2) | CN103028113B (sl) |
| AR (2) | AR052498A1 (sl) |
| AU (1) | AU2006222225B2 (sl) |
| BR (1) | BRPI0607840B1 (sl) |
| CA (2) | CA2882255C (sl) |
| CY (5) | CY1116108T1 (sl) |
| DK (4) | DK1858917T3 (sl) |
| EA (1) | EA011884B1 (sl) |
| ES (4) | ES2532803T3 (sl) |
| GB (1) | GB0504436D0 (sl) |
| HK (1) | HK1111427A1 (sl) |
| HR (4) | HRP20150142T1 (sl) |
| HU (4) | HUE032544T2 (sl) |
| IL (1) | IL185442A (sl) |
| LT (4) | LT2301955T (sl) |
| LU (1) | LUC00087I2 (sl) |
| MA (1) | MA29714B1 (sl) |
| MX (2) | MX346865B (sl) |
| MY (1) | MY148464A (sl) |
| NL (1) | NL300951I2 (sl) |
| NO (2) | NO341841B1 (sl) |
| NZ (1) | NZ561075A (sl) |
| PE (2) | PE20061287A1 (sl) |
| PL (4) | PL2281831T3 (sl) |
| PT (4) | PT2281831T (sl) |
| SI (4) | SI2281831T1 (sl) |
| TR (2) | TR201809397T4 (sl) |
| TW (1) | TWI403517B (sl) |
| UA (1) | UA94900C2 (sl) |
| WO (1) | WO2006094756A2 (sl) |
| ZA (1) | ZA200707144B (sl) |
Families Citing this family (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0504436D0 (en) * | 2005-03-03 | 2005-04-06 | Glaxosmithkline Biolog Sa | Vaccine |
| TWI457133B (zh) | 2005-12-13 | 2014-10-21 | Glaxosmithkline Biolog Sa | 新穎組合物 |
| CN101801412A (zh) * | 2007-07-19 | 2010-08-11 | 诺瓦瓦克斯股份有限公司 | 水痘带状疱疹病毒-病毒样颗粒(vlp)和抗原 |
| FR2952825B1 (fr) | 2009-11-24 | 2012-05-25 | Goaster Jacqueline Le | Utilisation d'un vaccin contre le virus vzv/hsv3 pour traiter les infections herpetiques par le virus hsv1 et/ou le virus hsv2 |
| SI2591114T1 (sl) | 2010-07-06 | 2016-10-28 | Glaxosmithkline Biologicals S.A. | Imunizacija velikih sesalcev z majhnimi odmerki RNA |
| BR112013000244A2 (pt) | 2010-07-06 | 2016-05-17 | Novartis Ag | lipossomas com lipídeos apresentando pka vantajoso para administração de rna |
| SI3243526T1 (sl) | 2010-07-06 | 2020-02-28 | Glaxosmithkline Biologicals S.A. | Dostava RNA za sprožitev večih imunskih poti |
| UA112970C2 (uk) * | 2010-08-05 | 2016-11-25 | Мерк Шарп Енд Доме Корп. | Інактивований вірус вітряної віспи, спосіб його одержання і застосування |
| SI2611461T1 (sl) | 2010-08-31 | 2022-08-31 | Glaxosmithkline Biologicals Sa | Pegilirani liposomi za dostavo imunogen-kodirajoče RNA |
| AU2011316707A1 (en) | 2010-10-11 | 2013-05-09 | Novartis Ag | Antigen delivery platforms |
| ES2656050T3 (es) | 2011-07-06 | 2018-02-22 | Glaxosmithkline Biologicals Sa | Composiciones de combinación inmunogénica y usos de las mismas |
| US9849066B2 (en) | 2013-04-24 | 2017-12-26 | Corning Incorporated | Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients |
| CN105530953A (zh) * | 2013-10-03 | 2016-04-27 | 日东电工株式会社 | 注射疫苗组合物 |
| JP6499420B2 (ja) * | 2014-11-13 | 2019-04-10 | 公益財団法人ヒューマンサイエンス振興財団 | ワクチン及び感染防御キット |
| US20180008700A1 (en) * | 2014-12-18 | 2018-01-11 | Glaxosmithkline Biologicals S.A. | Vaccination |
| BE1022523B1 (fr) * | 2014-12-18 | 2016-05-20 | Glaxosmithkline Biologicals Sa | Vaccination |
| BR112018008051A2 (pt) * | 2015-10-22 | 2018-11-13 | Modernatx Inc | vacinas de ácido nucleico para vírus de varicella zoster (vzv) |
| SI3718565T1 (sl) | 2015-10-22 | 2022-08-31 | Modernatx, Inc. | Cepiva za respiratorni virus |
| EP3370730A4 (en) | 2015-11-06 | 2019-07-31 | Adjuvance Technologies, Inc. | TRITERPENSAPONINANALOGA |
| EP3538146A4 (en) | 2016-11-11 | 2020-07-15 | ModernaTX, Inc. | INFLUENZA VACCINE |
| WO2018097642A1 (ko) * | 2016-11-25 | 2018-05-31 | 재단법인 목암생명과학연구소 | 바리셀라 조스터 바이러스 백신 |
| EP3545972A4 (en) * | 2016-11-25 | 2020-05-13 | Mogam Institute For Biomedical Research | VARICELLA AND ZONA VIRUS VACCINE |
| CN107022559A (zh) * | 2016-12-08 | 2017-08-08 | 长春祈健生物制品有限公司 | 一种水痘‑带状疱疹病毒糖蛋白e胞外区蛋白的制备方法 |
| GB201621686D0 (en) | 2016-12-20 | 2017-02-01 | Glaxosmithkline Biologicals Sa | Novel methods for inducing an immune response |
| WO2018124615A1 (ko) * | 2016-12-26 | 2018-07-05 | 재단법인 목암생명과학연구소 | 대상포진 백신 조성물 |
| CN108727503A (zh) * | 2017-04-18 | 2018-11-02 | 武汉博沃生物科技有限公司 | VZV重组gE-鞭毛素融合蛋白及其制备方法和应用 |
| CN110730666A (zh) * | 2017-04-25 | 2020-01-24 | 佐剂技术公司 | 三萜皂苷类似物 |
| SG10202108075YA (en) * | 2017-04-25 | 2021-09-29 | Adjuvance Technologies Inc | Triterpene saponin analogues |
| WO2018198085A1 (en) | 2017-04-28 | 2018-11-01 | Glaxosmithkline Biologicals Sa | Vaccination |
| GB201707700D0 (en) | 2017-05-12 | 2017-06-28 | Glaxosmithkline Biologicals Sa | Dried composition |
| IE20190084A3 (en) | 2017-05-30 | 2023-07-19 | Glaxosmithkline Biologicals Sa | Novel methods for manufacturing an adjuvant |
| US11324821B2 (en) | 2017-10-16 | 2022-05-10 | Adjuvance Technologies, Inc. | Triterpene saponin analogues |
| WO2019106192A1 (en) | 2017-12-01 | 2019-06-06 | Glaxosmithkline Biologicals Sa | Saponin purification |
| CN108315344A (zh) * | 2018-02-14 | 2018-07-24 | 武汉博沃生物科技有限公司 | Vzv糖蛋白e基因表达载体及其重组酵母菌株与应用 |
| KR20190121956A (ko) | 2018-04-19 | 2019-10-29 | 가천대학교 산학협력단 | 담팔수 추출물에서 분리한 화합물을 유효성분으로 함유하는 수두-대상포진 바이러스 억제용 약학적 조성물 |
| KR102337922B1 (ko) | 2018-04-19 | 2021-12-09 | 가천대학교 산학협력단 | 담팔수 추출물에서 분리한 화합물을 유효성분으로 함유하는 수두-대상포진 바이러스 억제용 약학적 조성물 |
| KR102683824B1 (ko) * | 2018-05-23 | 2024-07-18 | 재단법인 목암생명과학연구소 | 바리셀라 조스터 바이러스의 항원 변이체 및 이의 용도 |
| EP3833382A1 (en) | 2018-08-07 | 2021-06-16 | GlaxoSmithKline Biologicals S.A. | Processes and vaccines |
| CN108992667A (zh) * | 2018-08-09 | 2018-12-14 | 安徽智飞龙科马生物制药有限公司 | 一种带状疱疹疫苗及其制备方法、应用 |
| KR102270048B1 (ko) * | 2020-07-10 | 2021-06-28 | 주식회사 녹십자 | 바리셀라 조스터 바이러스 표면 단백질 항원의 생산 방법 |
| CN113164586B (zh) * | 2018-09-27 | 2024-04-16 | 武汉博沃生物科技有限公司 | 免疫组合物及其制备方法与应用 |
| EP3886901A1 (en) | 2018-11-29 | 2021-10-06 | GlaxoSmithKline Biologicals S.A. | Methods for manufacturing an adjuvant |
| CN109602901B (zh) * | 2019-01-08 | 2022-05-27 | 成都迈科康生物科技有限公司 | 一种带状疱疹病毒疫苗及其制备方法和应用 |
| WO2020190750A1 (en) | 2019-03-15 | 2020-09-24 | Modernatx, Inc. | Hiv rna vaccines |
| US20220235095A1 (en) | 2019-06-05 | 2022-07-28 | Glaxosmithkline Biologicals Sa | Saponin purification |
| CN112142828B (zh) * | 2019-06-28 | 2022-02-01 | 怡道生物科技(苏州)有限公司 | 一种gE基因及表达该基因的载体 |
| TW202128217A (zh) * | 2019-12-13 | 2021-08-01 | 大陸商遠大賽威信生命科學（南京）有限公司 | 醫藥組合物及其用途 |
| WO2021172971A1 (ko) * | 2020-02-28 | 2021-09-02 | (주)셀트리온 | 수두 대상포진 바이러스 융합 단백질 및 이를 포함하는 면역원성 조성물 |
| CA3188708A1 (en) | 2020-08-07 | 2022-02-10 | Access To Advanced Health Institute | Purified saponins and chromatographic process for purification of same |
| US20240033346A1 (en) * | 2020-09-11 | 2024-02-01 | Eubiologics Co., Ltd. | Vaccine composition for chickenpox or varicella zoster and method of using same |
| RU2750818C1 (ru) * | 2020-11-19 | 2021-07-05 | Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт вакцин и сывороток им. И.И. Мечникова" (ФГБНУ НИИВС им. И.И. Мечникова | Вирусный штамм для получения аттенуированной живой культуральной вакцины для профилактики и лечения опоясывающего герпеса для взрослого населения |
| WO2023056912A1 (en) * | 2021-10-08 | 2023-04-13 | Suzhou Abogen Biosciences Co., Ltd. | Nucleic acid vaccines for vzv |
| US20240366754A1 (en) | 2021-10-15 | 2024-11-07 | BioNTech SE | Pharmaceutical compositions for delivery of viral antigens and related methods |
| AU2022397292A1 (en) | 2021-11-24 | 2024-05-30 | Flagship Pioneering Innovations Vi, Llc | Varicella-zoster virus immunogen compositions and their uses |
| CN116350770B (zh) * | 2021-12-28 | 2024-07-12 | 成都迈科康生物科技有限公司 | 一种带状疱疹疫苗制剂及其制备方法 |
| WO2024017827A1 (en) | 2022-07-19 | 2024-01-25 | Glaxosmithkline Biologicals Sa | Continuous process for vaccine production |
| CN116655748B (zh) * | 2023-02-28 | 2024-07-26 | 易慧生物技术(上海)有限公司 | 一种截短型水痘-带状疱疹病毒gE蛋白及其应用 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5341202B2 (sl) | 1974-03-12 | 1978-11-01 | ||
| US4436727A (en) | 1982-05-26 | 1984-03-13 | Ribi Immunochem Research, Inc. | Refined detoxified endotoxin product |
| SE8205892D0 (sv) | 1982-10-18 | 1982-10-18 | Bror Morein | Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin |
| US4769239A (en) | 1984-08-21 | 1988-09-06 | Merck & Co., Inc. | Vaccine against varicella-zoster virus |
| CA1331443C (en) | 1987-05-29 | 1994-08-16 | Charlotte A. Kensil | Saponin adjuvant |
| US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
| US4912094B1 (en) | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
| DK0405867T3 (da) | 1989-06-27 | 1995-05-22 | Smithkline Beecham Biolog | Hidtil ukendte forbindelser |
| EP0468520A3 (en) | 1990-07-27 | 1992-07-01 | Mitsui Toatsu Chemicals, Inc. | Immunostimulatory remedies containing palindromic dna sequences |
| ZA929870B (en) | 1991-12-23 | 1993-08-18 | Duphar Int Res | Adjuvants |
| DK0671948T3 (da) | 1992-06-25 | 1997-09-01 | Smithkline Beecham Biolog | Vaccinepræparat indeholdende adjuvanser |
| AU687355B2 (en) * | 1992-07-17 | 1998-02-26 | Merck Sharp & Dohme Corp. | Method for preventing zoster or alleviating varicella related post-herpetic neuralgia |
| AU685443B2 (en) | 1993-03-23 | 1998-01-22 | Smithkline Beecham Biologicals (Sa) | Vaccine compositions containing 3-O deacylated monophosphoryl lipid A |
| US5976552A (en) * | 1995-04-28 | 1999-11-02 | Protein Sciences Corporation | Virus vaccines |
| GB9326253D0 (en) | 1993-12-23 | 1994-02-23 | Smithkline Beecham Biolog | Vaccines |
| EP1167377B2 (en) | 1994-07-15 | 2012-08-08 | University of Iowa Research Foundation | Immunomodulatory oligonucleotides |
| AUPM873294A0 (en) | 1994-10-12 | 1994-11-03 | Csl Limited | Saponin preparations and use thereof in iscoms |
| EP0817847B2 (en) * | 1995-03-23 | 2009-09-09 | Immunex Corporation | Il-17 receptor |
| US6846489B1 (en) | 1995-04-25 | 2005-01-25 | Smithkline Beecham Biologicals S.A. | Vaccines containing a saponin and a sterol |
| UA56132C2 (uk) * | 1995-04-25 | 2003-05-15 | Смітклайн Бічем Байолоджікалс С.А. | Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини |
| KR0177323B1 (ko) * | 1996-02-16 | 1999-04-01 | 성재갑 | 바이러스 백신 생산에 유용한 사람 이배체 폐세포 및 이를 이용한 수두 백신의 제조방법 |
| ES2227825T3 (es) | 1997-04-01 | 2005-04-01 | Corixa Corporation | Composiciones inmunologicas aduvantes acuosas de monofosforil lipido a. |
| GB9718901D0 (en) | 1997-09-05 | 1997-11-12 | Smithkline Beecham Biolog | Vaccine |
| EP1279401B1 (en) | 1997-09-05 | 2008-01-09 | GlaxoSmithKline Biologicals S.A. | Oil in water emulsions containing saponins |
| GB9901254D0 (en) * | 1999-01-20 | 1999-03-10 | Smithkline Beecham Biolog | Vaccines |
| JP2004511527A (ja) * | 2000-10-18 | 2004-04-15 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | ワクチン |
| GB0504436D0 (en) * | 2005-03-03 | 2005-04-06 | Glaxosmithkline Biolog Sa | Vaccine |
-
2005
- 2005-03-03 GB GBGB0504436.7A patent/GB0504436D0/en not_active Ceased
-
2006
- 2006-03-01 PT PT101882561T patent/PT2281831T/pt unknown
- 2006-03-01 NZ NZ561075A patent/NZ561075A/en not_active IP Right Cessation
- 2006-03-01 DK DK06707446.8T patent/DK1858917T3/da active
- 2006-03-01 PL PL10188256T patent/PL2281831T3/pl unknown
- 2006-03-01 HU HUE10188214A patent/HUE032544T2/en unknown
- 2006-03-01 LT LTEP10188215.7T patent/LT2301955T/lt unknown
- 2006-03-01 AR ARP060100773A patent/AR052498A1/es not_active Application Discontinuation
- 2006-03-01 EP EP10188214.0A patent/EP2281830B1/en active Active
- 2006-03-01 EA EA200701632A patent/EA011884B1/ru not_active IP Right Cessation
- 2006-03-01 SI SI200632265T patent/SI2281831T1/sl unknown
- 2006-03-01 KR KR1020137034242A patent/KR20140006115A/ko not_active Application Discontinuation
- 2006-03-01 SI SI200632264T patent/SI2301955T1/sl unknown
- 2006-03-01 WO PCT/EP2006/002070 patent/WO2006094756A2/en active Application Filing
- 2006-03-01 MX MX2012004471A patent/MX346865B/es unknown
- 2006-03-01 BR BRPI0607840-0A patent/BRPI0607840B1/pt active IP Right Grant
- 2006-03-01 UA UAA200709537A patent/UA94900C2/uk unknown
- 2006-03-01 EP EP20060707446 patent/EP1858917B8/en active Active
- 2006-03-01 MX MX2007010626A patent/MX2007010626A/es active IP Right Grant
- 2006-03-01 DK DK10188256.1T patent/DK2281831T3/en active
- 2006-03-01 CA CA2882255A patent/CA2882255C/en active Active
- 2006-03-01 EP EP10188256.1A patent/EP2281831B1/en active Active
- 2006-03-01 US US11/817,175 patent/US20080171079A1/en not_active Abandoned
- 2006-03-01 PE PE2006000237A patent/PE20061287A1/es not_active Application Discontinuation
- 2006-03-01 SI SI200631890T patent/SI1858917T1/sl unknown
- 2006-03-01 CN CN201210552767.6A patent/CN103028113B/zh active Active
- 2006-03-01 DK DK10188214.0T patent/DK2281830T3/en active
- 2006-03-01 ES ES06707446.8T patent/ES2532803T3/es active Active
- 2006-03-01 CN CN2006800152455A patent/CN101189254B/zh active Active
- 2006-03-01 LT LTEP10188214.0T patent/LT2281830T/lt unknown
- 2006-03-01 PL PL10188215T patent/PL2301955T3/pl unknown
- 2006-03-01 AU AU2006222225A patent/AU2006222225B2/en active Active
- 2006-03-01 CA CA2600905A patent/CA2600905C/en active Active
- 2006-03-01 JP JP2007557447A patent/JP5420842B2/ja active Active
- 2006-03-01 LT LTEP10188256.1T patent/LT2281831T/lt unknown
- 2006-03-01 KR KR1020077022672A patent/KR101357204B1/ko active Protection Beyond IP Right Term
- 2006-03-01 ES ES10188256.1T patent/ES2675055T3/es active Active
- 2006-03-01 EP EP10188215.7A patent/EP2301955B1/en active Active
- 2006-03-01 MY MYPI20060879A patent/MY148464A/en unknown
- 2006-03-01 PL PL10188214T patent/PL2281830T3/pl unknown
- 2006-03-01 TR TR2018/09397T patent/TR201809397T4/tr unknown
- 2006-03-01 ES ES10188215.7T patent/ES2675054T3/es active Active
- 2006-03-01 SI SI200632138A patent/SI2281830T1/sl unknown
- 2006-03-01 HU HUE10188215A patent/HUE038468T2/hu unknown
- 2006-03-01 DK DK10188215.7T patent/DK2301955T3/en active
- 2006-03-01 TR TR2018/09393T patent/TR201809393T4/tr unknown
- 2006-03-01 ES ES10188214.0T patent/ES2618037T3/es active Active
- 2006-03-01 PL PL06707446T patent/PL1858917T3/pl unknown
- 2006-03-01 TW TW095106863A patent/TWI403517B/zh not_active IP Right Cessation
- 2006-03-01 PT PT101882157T patent/PT2301955T/pt unknown
- 2006-03-01 PT PT101882140T patent/PT2281830T/pt unknown
- 2006-03-01 PT PT67074468T patent/PT1858917E/pt unknown
- 2006-03-01 PE PE2010000522A patent/PE20100658A1/es not_active Application Discontinuation
- 2006-03-01 HU HUE10188256A patent/HUE038467T2/hu unknown
-
2007
- 2007-08-22 IL IL185442A patent/IL185442A/en active IP Right Grant
- 2007-08-23 ZA ZA200707144A patent/ZA200707144B/xx unknown
- 2007-08-29 NO NO20074392A patent/NO341841B1/no active Protection Beyond IP Right Term
- 2007-09-24 MA MA30239A patent/MA29714B1/fr unknown
-
2008
- 2008-02-25 HK HK08102085.4A patent/HK1111427A1/xx not_active IP Right Cessation
-
2010
- 2010-05-20 US US12/784,296 patent/US20110045059A1/en not_active Abandoned
-
2011
- 2011-01-07 US US12/986,928 patent/US7939084B1/en active Active
-
2013
- 2013-04-08 JP JP2013080447A patent/JP5840167B2/ja active Active
-
2015
- 2015-02-04 HR HRP20150142TT patent/HRP20150142T1/hr unknown
- 2015-02-20 CY CY20151100179T patent/CY1116108T1/el unknown
-
2017
- 2017-01-03 AR ARP170100008A patent/AR107285A2/es not_active Application Discontinuation
- 2017-01-18 HR HRP20170081TT patent/HRP20170081T1/hr unknown
- 2017-02-10 CY CY20171100188T patent/CY1118629T1/el unknown
-
2018
- 2018-06-19 CY CY20181100636T patent/CY1121211T1/el unknown
- 2018-06-19 CY CY20181100637T patent/CY1120347T1/el unknown
- 2018-06-26 HR HRP20180989TT patent/HRP20180989T1/hr unknown
- 2018-06-26 HR HRP20180988TT patent/HRP20180988T1/hr unknown
- 2018-09-17 CY CY2018025C patent/CY2018025I2/el unknown
- 2018-09-20 NL NL300951C patent/NL300951I2/nl unknown
- 2018-09-20 NO NO2018033C patent/NO2018033I1/no unknown
- 2018-09-20 LT LTPA2018012C patent/LTC2281831I2/lt unknown
- 2018-09-20 LU LU00087C patent/LUC00087I2/fr unknown
- 2018-09-20 HU HUS1800038C patent/HUS1800038I1/hu unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SI2301955T1 (sl) | Cepivo proti virusu varicella zoster | |
| JP2008531637A5 (sl) | ||
| BR9809655A (pt) | Uso de derivados do ácido fumárico | |
| CA2563185A1 (en) | Sustained release formulations of a peptide or protein and a purified gallic acid ester | |
| ES2293708T3 (es) | Vacunas que contienen una saponina y un esterol. | |
| CA2376978A1 (en) | Compositions and methods for treatment of sexual dysfunction | |
| WO2005023866A3 (en) | Peptides that inhibit complement activation | |
| JP2013543497A5 (sl) | ||
| MX2009001200A (es) | Uso antiviral de un tensoactivo cationico. | |
| BR9907866A (pt) | Composição farmacêutica compreendendo uma combinação de metformina e fibrato, e seu uso para a preparação de medicinas destinadas a reduzir a hiperglicemia | |
| HRP20110965T1 (hr) | Nove formulacije peptida povezanih s tumorima koji se vežu za molekule ljudskog leukocitnog antigena (hla) klase i ili ii za cjepiva | |
| ATE311373T1 (de) | Oxadiazolverbindungen und -zusammensetzungen zur abgabe von wirkstoffen | |
| RU2010111139A (ru) | Комбинированная терапия рака поджелудочной железы с использованием антигенного пептида и химиотерапевтического средства | |
| ATE413865T1 (de) | Zusammensetzungen mit alphahydroxy-säureester zur wirkstofffreisetzung und anwendungsverfahren dafür | |
| EP2270035A3 (en) | Peptides enhancing CEH activity, pharmaceutical compositions comprising these peptides and their use in the treatment of atherosclerosis | |
| GB2375519A (en) | Biodegradable funerary urn | |
| BR0110892A (pt) | Forma de administração farmacêutica para peptìdios, processos para preparação e uso dos mesmos | |
| WO2008063865A3 (en) | Biphosphonate inhalant formulations and methods for using the same | |
| JP2012516693A5 (sl) | ||
| WO2002032378A3 (en) | Fusion cells and cytokine compositions for treatment of disease | |
| WO2006023665A3 (en) | Il-1 antagonist formulations | |
| KR890003409A (ko) | 점막 투여시 흡수 촉진제로서의 시클릭 펩티드 | |
| RU2014116256A (ru) | Улучшенные составы рекомбинантной человеческой липазы, стимулируемой солями желчных кислот | |
| WO2009023714A3 (en) | Compositions and methods for the treatment and prophylaxis of hypertension | |
| WO2004028457A3 (en) | PHARMACEUTICAL COMPOSITION FOR IMPROVED ADMINISTRATION OF HIV gp41-DERIVED PEPTIDES, AND ITS USE IN THERAPY |